Literature DB >> 33429859

Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity.

Mari Lahelma1,2, Panu K Luukkonen1,2,3, Sami Qadri1,2, Noora Ahlholm1,2, Susanna Lallukka-Brück1,2, Kimmo Porthan1,2, Anne Juuti4, Henna Sammalkorpi4, Anne K Penttilä4, Johanna Arola5, Marju Orho-Melander6, Hannele Yki-Järvinen1,2.   

Abstract

Only some individuals with obesity develop liver fibrosis due to non-alcoholic fatty liver disease (NAFLD-fibrosis). We determined whether detailed assessment of lifestyle factors in addition to physical, biochemical and genetic factors helps in identification of these patients. A total of 100 patients with obesity (mean BMI 40.0 ± 0.6 kg/m2) referred for bariatric surgery at the Helsinki University Hospital underwent a liver biopsy to evaluate liver histology. Physical activity was determined by accelerometer recordings and by the Modifiable Activity Questionnaire, diet by the FINRISK Food Frequency Questionnaire, and other lifestyle factors, such as sleep patterns and smoking, by face-to-face interviews. Physical and biochemical parameters and genetic risk score (GRS based on variants in PNPLA3, TM6SF2, MBOAT7 and HSD17B13) were measured. Of all participants 49% had NAFLD-fibrosis. Independent predictors of NAFLD-fibrosis were low moderate-to-vigorous physical activity, high red meat intake, low carbohydrate intake, smoking, HbA1c, triglycerides and GRS. A model including these factors (areas under the receiver operating characteristics curve (AUROC) 0.90 (95% CI 0.84-0.96)) identified NAFLD-fibrosis significantly more accurately than a model including all but lifestyle factors (AUROC 0.82 (95% CI 0.73-0.91)) or models including lifestyle, physical and biochemical, or genetic factors alone. Assessment of lifestyle parameters in addition to physical, biochemical and genetic factors helps to identify obese patients with NAFLD-fibrosis.

Entities:  

Keywords:  diet; glucose; insulin; physical activity; stress

Mesh:

Year:  2021        PMID: 33429859      PMCID: PMC7827136          DOI: 10.3390/nu13010169

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  44 in total

1.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

3.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

4.  Hepatic histology in obese patients undergoing bariatric surgery.

Authors:  Mariana Machado; Pedro Marques-Vidal; Helena Cortez-Pinto
Journal:  J Hepatol       Date:  2006-07-25       Impact factor: 25.083

5.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

6.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

7.  Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.

Authors:  Helene Gellert-Kristensen; Tom G Richardson; George Davey Smith; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Stefan Stender
Journal:  Hepatology       Date:  2020-09       Impact factor: 17.425

8.  MEDITERRANEAN DIET IS ASSOCIATED WITH LIVER HISTOLOGY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE.

Authors:  Rocio Aller; Olatz Izaola; Beatriz de la Fuente; Daniel Antonio De Luis Román
Journal:  Nutr Hosp       Date:  2015-12-01       Impact factor: 1.057

9.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Amy G Shah; Alison Lydecker; Karen Murray; Brent N Tetri; Melissa J Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-10       Impact factor: 11.382

Review 10.  Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

Authors:  I N Guha; J Parkes; P R Roderick; S Harris; W M Rosenberg
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

View more
  1 in total

1.  High Meat Consumption Is Prospectively Associated with the Risk of Non-Alcoholic Fatty Liver Disease and Presumed Significant Fibrosis.

Authors:  Dana Ivancovsky-Wajcman; Naomi Fliss-Isakov; Laura Sol Grinshpan; Federico Salomone; Jeffrey V Lazarus; Muriel Webb; Oren Shibolet; Revital Kariv; Shira Zelber-Sagi
Journal:  Nutrients       Date:  2022-08-27       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.